Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/AJANTPHARM stock hub

NSE/AJANTPHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/AJANTPHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

379B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/AJANTPHARM

In the news

Latest news · NSE/AJANTPHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E30.8

P25 24.9P50 32.4P75 45.7

Trailing P/E35.9

P25 24.8P50 35.9P75 56.9

ROE25.4

P25 6.3P50 13.6P75 18.1

ROIC27.6

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/AJANTPHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

247

Groups with data

Currency

INR

Showing 247 of 247 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	9,628
Employees Change	1,555%
Employees Change Percent	19.26
Enterprise value	INR 375B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE031B01049
Last refreshed	2026-05-10
Market cap	INR 379B
Price	INR 3,033
Price currency	INR
Rev Per Employee	5,842,262.15x
Sector	Healthcare
Sic	2834
Symbol	nse/AJANTPHARM
Website	https://www.ajantapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.79%
EV Earnings	35.51x
EV/EBIT	26.9x
EV/EBITDA	23.93x
EV/FCF	228.61x
EV/Sales	6.67x
FCF yield	0.43%
Forward P/E	30.78x
P/B ratio	8.37x
P/E ratio	35.91x
P/S ratio	6.74x
PE Ratio10 Y	28.27x
PE Ratio3 Y	35.22x
PE Ratio5 Y	31.22x
PEG ratio	2.03x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	24.78%
EBITDA Margin	27.86%
FCF margin	2.92%
Gross margin	78.96%
Gross Profit	INR 44.4B
Gross Profit Growth	26.7%
Gross Profit Growth Q	44.6%
Gross Profit Growth3 Y	19.05%
Gross Profit Growth5 Y	15.02%
Net Income	INR 10.6B
Net Income Growth	14.73%
Net Income Growth Q	18.4%
Net Income Growth Quarters	12%
Net Income Growth Years	3%
Net Income Growth3 Y	21.55%
Net Income Growth5 Y	10.06%
Pretax Margin	24.49%
Profit Margin	18.77%
Profit Per Employee	INR 1.1M
Profitable Years	22
ROA	15.6
Roa5y	13.37
ROCE	29.41
ROE	25.39
Roe5y	22.87
ROIC	27.59
Roic5y	25

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	12.45%
Cagr15y	39.9%
Cagr1y	22.8%
Cagr20y	36.04%
Cagr3y	34.74%
Cagr5y	19%
Div CAGR10	11.61%
Div CAGR3	-4.35%
Div CAGR5	34.62%
EPS Growth	14.93
EPS Growth Q	18.56
EPS Growth Quarters	12
EPS Growth Years	3
EPS Growth3 Y	22.57
EPS Growth5 Y	11.04
FCF Growth	-80.46%
FCF Growth3 Y	-35.72%
FCF Growth5 Y	-16.52%
OCF Growth	-54.27%
OCF Growth10 Y	4.96%
OCF Growth3 Y	-12.58%
OCF Growth5 Y	-1.69%
Revenue Growth	21.02x
Revenue Growth Q	26.71x
Revenue Growth Quarters	28x
Revenue Growth Years	7x
Revenue Growth3 Y	14.55x
Revenue Growth5 Y	14.25x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	INR 1.01
Assets	INR 61.5B
Cash	INR 6.6B
Current Assets	INR 37.4B
Current Liabilities	INR 14.2B
Debt	INR 2.6B
Debt EBITDA	INR 0.17
Debt Equity	INR 0.06
Debt FCF	INR 1.59
Equity	INR 45.3B
Interest Coverage	86.52
Liabilities	INR 16.3B
Long Term Assets	INR 24.2B
Long Term Liabilities	INR 2.1B
Net Cash	INR 4B
Net Cash By Market Cap	INR 1.07
Net Cash Growth	-28.15%
Net Debt EBITDA	INR -0.26
Net Debt Equity	INR -0.09
Net Debt FCF	INR -2.47
Tangible Book Value	INR 44.9B
Tangible Book Value Per Share	INR 359
WACC	5.34

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.64
Inventory Turnover	1.29
Net Working Capital	INR 18.8B
Quick ratio	1.78
Working Capital	INR 23.2B
Working Capital Turnover	INR 2.7

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.18%
Dividend Growth	-48.15%
Dividend Growth Years	0%
Dividend per share	INR 28
Dividend Years	20
Dividend Yield	0.92%
Ex Div Date	2025-11-10
Last Dividend	INR 28
Payout Frequency	Annual
Payout Ratio	33.12%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	223.15%
1Y total return	22.78%
200-day SMA	2,698.8
3Y total return	144.68%
50-day SMA	2,894
50-day SMA vs 200-day SMA	50over200
5Y total return	138.57%
All Time High	3,485
All Time High Change	-12.97%
All Time High Date	2024-09-12
All Time Low	1.82
All Time Low Change	166,365.42%
All Time Low Date	2003-03-28
ATR	87.89
Beta	0.2
Beta1y	0.26
Beta2y	0.16
Ch YTD	9.54
High	3,095
High52	3,228
High52 Date	2026-03-13
High52ch	-6.04%
Low	3,027.7
Low52	2,329.9
Low52 Date	2025-09-30
Low52ch	30.18%
Ma50ch	4.8%
Price vs 200-day SMA	12.38%
RSI	63.35
RSI Monthly	63.36
RSI Weekly	62.72
Sharpe ratio	0.64x
Sortino ratio	1.27
Total Return	1.1%
Tr YTD	9.54
Tr15y	15,290.75%
Tr1m	11.85%
Tr1w	4.56%
Tr3m	6.32%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 13.9B
Operating Income Growth	23.51
Operating Income Growth Q	36.21
Operating Income Growth3 Y	27.04
Operating Income Growth5 Y	9.38
Operating margin	24.78

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,961,365%
Net Borrowing	2,094,000,000
Shares Insiders	42.24%
Shares Institutions	22.03%
Shares Out	124,887,774
Shares Qo Q	0.02%
Shares Yo Y	-0.18%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	INR 1.6B
Average Volume	115,878.2x
Bv Per Share	362.4
CAPEX	INR -3.7B
Ch10y	194.9
Ch15y	13,254.8
Ch1m	11.85
Ch1w	4.56
Ch1y	21.42
Ch20y	36,275.6
Ch3m	6.32
Ch3y	133.6
Ch5y	125.5
Ch6m	20.16
Change	-1.47%
Change From Open	-1.52
Close	3,078.4
Days Gap	0.05
Depreciation Amortization	1,731,400,000
Dollar Volume	169,623,558
Earnings Date	2026-05-05
EBIT	INR 13.9B
EBITDA	INR 15.7B
EPS	INR 84.51
F Score	5
FCF	INR 1.6B
FCF EV Yield	0.44x
FCF Per Share	INR 13.13
Financing CF	-1,679,200,000
Fiscal Year End	March
Founded	1,973
Graham Number	830.12273
Graham Upside	-72.63
Income Tax	INR 3.2B
Investing CF	-4,289,200,000
Is Primary Listing	1
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Date	2022-06-22
Last Split Type	Forward
Lynch Fair Value	INR 850
Lynch Upside	-71.97
Ma150	2,719.9
Ma150ch	11.51%
Ma20	2,852.6
Ma20ch	6.33%
Net CF	-676,500,000
Next Earnings Date	2026-07-29
Open	3,079.8
P FCF Ratio	231.1
P OCF Ratio	71.63
Payment Date	2025-12-03
Position In Range	7.88
Ppne	20,834,200,000
Price Date	2026-05-08
Price EBITDA	INR 24.19
Ptbv Ratio	8.45
Relative Volume	0.47x
Revenue	56,249,300,000x
SBC By Revenue	0.03x
Share Based Comp	15,300,000
Tax By Revenue	5.72x
Tax Rate	23.35%
Tr20y	47,001.42%
Tr6m	21.51%
Volume	55,926

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/AJANTPHARM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.9%

$28.0 annual per share

Payout ratio

+33.1%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+34.6%

0 consecutive years of growth

Total shareholder yield

+1.1%

Next ex-dividend date: 2025-11-10

Performance

NSE/AJANTPHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/AJANTPHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.0%

Share of float held by funds and institutions

Insider ownership

+42.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.2%

Negative means the company is buying back shares.

Technical

NSE/AJANTPHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

63.3

Neutral momentum band

Price vs 200-day MA

+12.4%

50/200-day relationship not available

Beta (5Y)

0.20

Less volatile than the market

Sharpe ratio

0.64

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/AJANTPHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/AJANTPHARM stock rating?

nse/AJANTPHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/AJANTPHARM analysis?

The full report lives at /stocks/nse/AJANTPHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/AJANTPHARM?

The latest report frames nse/AJANTPHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/AJANTPHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.